NCT01490736View on ClinicalTrials.gov

Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2013

Conditions
Acne
Interventions
DRUG

Lemuteporfin

lemuteporfin topical solution, 1%

Trial Locations (1)

H2K 4L5

Innovaderm Research, Inc, Montreal

Sponsors

Lead Sponsor

Dermira, Inc.
All Listed Sponsors
lead

Dermira, Inc.

INDUSTRY

NCT01490736 - Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne | Biotech Hunter | Biotech Hunter